{"id":54892,"date":"2026-01-20T20:41:28","date_gmt":"2026-01-20T12:41:28","guid":{"rendered":"https:\/\/flcube.com\/?p=54892"},"modified":"2026-01-20T20:41:29","modified_gmt":"2026-01-20T12:41:29","slug":"aim-vaccines-pcv20-gets-nmpa-clinical-approval-challenging-pfizers-monopoly","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54892","title":{"rendered":"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly"},"content":{"rendered":"\n<p><strong>AIM Vaccine Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6660:HKG\">HKG: 6660<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved clinical trials for its <strong>20\u2011valent pneumococcal conjugate vaccine (PCV20)<\/strong>, a next\u2011generation version of its marketed PCV13 that adds seven serotypes to cover 20 major circulating strains, positioning the company as a <strong>domestic challenger<\/strong> to Pfizer\u2019s <strong>Prevenar 20<\/strong> in the world\u2019s largest vaccine market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AIM Vaccine Co., Ltd (6660.HK)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>20\u2011valent pneumococcal conjugate vaccine (PCV20)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Clinical Trial Application (CTA)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of invasive pneumococcal disease (pneumonia, meningitis, bacteremia)<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Individuals from 2 months of age (\u22656 weeks)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>15\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First PCV20 in China; adds 7 serotypes vs. PCV13; no domestic competitor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-development\">Drug Profile &amp; Development<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> Optimized iteration of AIM\u2019s <strong>marketed PCV13<\/strong> with <strong>7 additional serotypes<\/strong>, covering <strong>20 major circulating pneumococcal strains<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> <strong>Protein\u2011polysaccharide conjugate<\/strong> technology induces T\u2011cell dependent immune response, producing <strong>high\u2011titer, long\u2011lasting antibodies<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> <strong>Broad age range<\/strong> from 6 weeks (2 months) through adulthood, simplifying immunization schedules<\/li>\n\n\n\n<li><strong>Clinical Need:<\/strong> <strong>Invasive pneumococcal disease<\/strong> remains a leading cause of <strong>infant mortality<\/strong> in China; MDR serotypes increasing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Annual Births (Target Cohort)<\/strong><\/td><td>9.5\u202fmillion<\/td><td>135\u202fmillion<\/td><\/tr><tr><td><strong>PCV Coverage Rate (China)<\/strong><\/td><td>35% (2025)<\/td><td>70\u201180% (developed markets)<\/td><\/tr><tr><td><strong>Addressable Market (2030E)<\/strong><\/td><td>\u00a528\u202fbillion<\/td><td>$8.5\u202fbillion<\/td><\/tr><tr><td><strong>Pfizer Prevenar 20 Status<\/strong><\/td><td>Not approved in China<\/td><td>Approved in US, EU, Japan<\/td><\/tr><tr><td><strong>AIM PCV20 Peak Share<\/strong><\/td><td>18%<\/td><td>2%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u00a55.0\u202fbillion<\/td><td>$170\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pfizer Prevenar 20<\/strong> \u2013 Market leader globally, <strong>not yet filed in China<\/strong> (regulatory delay)<\/li>\n\n\n\n<li><strong>Pfizer Prevenar 13<\/strong> \u2013 Currently dominates Chinese private market (\u00a54.2\u202fbillion sales)<\/li>\n\n\n\n<li><strong>Domestic PCV13<\/strong> \u2013 <strong>3 local players<\/strong> (Walvax, Minhai, Sinovac) with <strong>NRDL pricing<\/strong> (\u00a5600\/dose)<\/li>\n\n\n\n<li><strong>AIM PCV20<\/strong> \u2013 <strong>First 20\u2011valent<\/strong> domestically; <strong>potential for premium pricing<\/strong> (\u00a51,200\u20111,500\/dose) and <strong>NRDL fast\u2011track<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> AIM\u2019s <strong>Changchun facility<\/strong> (capacity 80\u202fmillion doses\/year) can produce PCV20 with <strong>minimal retrofit<\/strong>; <strong>WHO Pre\u2011qualification<\/strong> targeted by 2028 for UN procurement<\/li>\n\n\n\n<li><strong>Clinical Pathway:<\/strong> <strong>Phase\u202fI\/II bridging study<\/strong> vs. Prevenar 20 planned <strong>Q2\u202f2026<\/strong>; <strong>Phase\u202fIII superiority trial<\/strong> to demonstrate <strong>broader serotype coverage vs. PCV13<\/strong><\/li>\n\n\n\n<li><strong>Commercialization:<\/strong> <strong>Existing 2,000\u2011hospital distribution network<\/strong> for PCV13 can be leveraged; <strong>private market launch<\/strong> expected <strong>2028<\/strong>, <strong>NRDL negotiation<\/strong> in 2029<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> <strong>Ex\u2011China licensing<\/strong> discussions underway with <strong>GSK<\/strong> and <strong>Serum Institute<\/strong> for <strong>low\u2011middle income markets<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, market penetration, and revenue forecasts for PCV20. Actual results may differ due to competitive responses, regulatory delays, and vaccine hesitancy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011900836_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026011900836_c.\"><\/object><a id=\"wp-block-file--media-82e6c454-aaad-45d0-a3cd-3457c4ca2bb5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011900836_c.pdf\">2026011900836_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2026011900836_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-82e6c454-aaad-45d0-a3cd-3457c4ca2bb5\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AIM Vaccine Co., Ltd (HKG: 6660) announced that China\u2019s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[705,62,1401,12],"class_list":["post-54892","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-aim-vaccine","tag-clinical-trial-approval-initiation","tag-hkg-6660","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AIM Vaccine Co., Ltd (HKG: 6660) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for its 20\u2011valent pneumococcal conjugate vaccine (PCV20), a next\u2011generation version of its marketed PCV13 that adds seven serotypes to cover 20 major circulating strains, positioning the company as a domestic challenger to Pfizer\u2019s Prevenar 20 in the world\u2019s largest vaccine market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54892\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly\" \/>\n<meta property=\"og:description\" content=\"AIM Vaccine Co., Ltd (HKG: 6660) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for its 20\u2011valent pneumococcal conjugate vaccine (PCV20), a next\u2011generation version of its marketed PCV13 that adds seven serotypes to cover 20 major circulating strains, positioning the company as a domestic challenger to Pfizer\u2019s Prevenar 20 in the world\u2019s largest vaccine market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54892\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T12:41:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T12:41:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54892#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54892\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly\",\"datePublished\":\"2026-01-20T12:41:28+00:00\",\"dateModified\":\"2026-01-20T12:41:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54892\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AIM Vaccine\",\"Clinical trial approval \\\/ initiation\",\"HKG: 6660\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54892#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54892\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54892\",\"name\":\"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-20T12:41:28+00:00\",\"dateModified\":\"2026-01-20T12:41:29+00:00\",\"description\":\"AIM Vaccine Co., Ltd (HKG: 6660) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for its 20\u2011valent pneumococcal conjugate vaccine (PCV20), a next\u2011generation version of its marketed PCV13 that adds seven serotypes to cover 20 major circulating strains, positioning the company as a domestic challenger to Pfizer\u2019s Prevenar 20 in the world\u2019s largest vaccine market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54892#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54892\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54892#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly - Insight, China&#039;s Pharmaceutical Industry","description":"AIM Vaccine Co., Ltd (HKG: 6660) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for its 20\u2011valent pneumococcal conjugate vaccine (PCV20), a next\u2011generation version of its marketed PCV13 that adds seven serotypes to cover 20 major circulating strains, positioning the company as a domestic challenger to Pfizer\u2019s Prevenar 20 in the world\u2019s largest vaccine market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54892","og_locale":"en_US","og_type":"article","og_title":"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly","og_description":"AIM Vaccine Co., Ltd (HKG: 6660) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for its 20\u2011valent pneumococcal conjugate vaccine (PCV20), a next\u2011generation version of its marketed PCV13 that adds seven serotypes to cover 20 major circulating strains, positioning the company as a domestic challenger to Pfizer\u2019s Prevenar 20 in the world\u2019s largest vaccine market.","og_url":"https:\/\/flcube.com\/?p=54892","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-20T12:41:28+00:00","article_modified_time":"2026-01-20T12:41:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54892#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54892"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly","datePublished":"2026-01-20T12:41:28+00:00","dateModified":"2026-01-20T12:41:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54892"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AIM Vaccine","Clinical trial approval \/ initiation","HKG: 6660","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54892#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54892","url":"https:\/\/flcube.com\/?p=54892","name":"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-20T12:41:28+00:00","dateModified":"2026-01-20T12:41:29+00:00","description":"AIM Vaccine Co., Ltd (HKG: 6660) announced that China\u2019s National Medical Products Administration (NMPA) has approved clinical trials for its 20\u2011valent pneumococcal conjugate vaccine (PCV20), a next\u2011generation version of its marketed PCV13 that adds seven serotypes to cover 20 major circulating strains, positioning the company as a domestic challenger to Pfizer\u2019s Prevenar 20 in the world\u2019s largest vaccine market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54892#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54892"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54892#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AIM Vaccine\u2019s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer\u2019s Monopoly"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54892"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54892\/revisions"}],"predecessor-version":[{"id":54895,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54892\/revisions\/54895"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}